Persimmon Plc (OTCMKTS:PSMMY – Get Rating) – Stock analysts at Jefferies Financial Group raised their FY2022 earnings per share (EPS) estimates for shares of Persimmon in a note issued to investors on Monday, January 23rd. Jefferies Financial Group analyst G. Johnson now forecasts that the company will post earnings per share of $6.16 for the year, up from their prior forecast of $6.06. Jefferies Financial Group has a “Hold” rating on the stock. The consensus estimate for Persimmon’s current full-year earnings is $5.99 per share.
A number of other research analysts also recently commented on PSMMY. UBS Group downgraded Persimmon from a “neutral” rating to a “sell” rating and reduced their target price for the stock from GBX 1,290 ($15.97) to GBX 1,230 ($15.23) in a report on Monday, November 28th. Investec cut Persimmon from a “buy” rating to a “hold” rating in a research report on Wednesday, December 7th. Morgan Stanley dropped their price target on Persimmon from GBX 1,480 ($18.32) to GBX 1,117 ($13.83) and set an “underweight” rating on the stock in a research report on Wednesday, October 26th. Barclays began coverage on Persimmon in a research report on Monday, December 5th. They set an “underweight” rating and a GBX 1,360 ($16.84) price target on the stock. Finally, Bank Of America (Bofa) cut Persimmon from a “buy” rating to a “neutral” rating in a research report on Monday, November 28th. Four research analysts have rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $1,477.40.
Persimmon Stock Up 1.1 %
Persimmon Company Profile
Persimmon Plc, together with its subsidiaries, operates as a house builder in the United Kingdom. The company offers family housing under the Persimmon Homes brand name; executive housing under the Charles Church brand name; and social housing under the Westbury Partnerships brand name. It also provides broadband services.
- Get a free copy of the StockNews.com research report on Persimmon (PSMMY)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Persimmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Persimmon and related companies with MarketBeat.com's FREE daily email newsletter.